SAN FRANCISCO – Gilead Sciences Inc.'s president and chief operating officer, John Milligan, told attendees of the 33rd annual J.P. Morgan Healthcare Conference that the Foster City, Calif.-based company's hepatitis C virus (HCV) therapy Sovaldi (sofosbuvir) is now broadly covered across most of the health plans in America and is making continuing progress in Europe, providing access for more patients than ever before.